## SUMMARY

In one aspect of the present disclosure, there is provided an IL-6 inhibitor for use in the treatment of retinal inflammation.

In another aspect of the present disclosure, there is provided use of an IL-6 inhibitor in the manufacture of a medicament for the treatment of retinal inflammation.

This ~~invention~~ present disclosure thus relates to a preventive and/or therapeutic agent for use in the treatment of retinal inflammation wherein said preventive and/or therapeutic agent comprises an IL-6 inhibitor, an APOE inhibitor and/or a Fas activator as an active ingredient.

In a particular embodiment of the present ~~invention~~disclosure, the said retinal inflammation comprises atrophic age-related macular degeneration (atrophic AMD) and retinitis pigmentosa. In a preferred embodiment, the ~~invention~~ present disclosure relates to a preventive and/or therapeutic agent for use in the treatment of atrophic age-related macular degeneration (atrophic AMD).

In a particular embodiment, the said IL-6 inhibitor for use in the ~~invention~~ present disclosure comprises (i) an antagonist of IL-6 activity, such as an antibody recognizing IL-6, a soluble IL-6 receptor or an inhibitor of IL-6 translation or (ii) an antagonist of IL-6 receptor, such as an antibody recognizing IL-6R or an IL-6R binding peptide.

In a particular embodiment, the said APOE inhibitor for use in the ~~invention~~ present disclosure comprises an antibody directed against APOE, an inhibitor of APOE translation or a soluble APOE receptor or a functional fragment thereof.

In an embodiment of the ~~invention~~present disclosure, the said Fas activator comprises a Fas agonist, such as FasL or functional fragments thereof, or FasL-mimicking peptides.

In an embodiment of the ~~invention~~present disclosure, the said preventive and/or therapeutic agent is delivered intra-vitreously.

In an embodiment of the ~~invention~~present disclosure, the said preventive and/or therapeutic agent comprises an IL-6 inhibitor and/or an APOE inhibitor, each in a concentration of from 5mg/mL to 500mg/mL.